Search company, investor...



Acquired | Acquired


XENIOS is the therapy and technology leader in minimally invasive lung and heart assist.

Headquarters Location

Im Zukunftspark 1

Heilbronn, 74076,


+49 7131 2706 0

Missing: XENIOS's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: XENIOS's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing XENIOS

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

XENIOS is included in 2 Expert Collections, including Medical Devices.


Medical Devices

8,614 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.


Health IT

7,901 items

XENIOS Patents

XENIOS has filed 21 patents.

The 3 most popular patent topics include:

  • Intensive care medicine
  • Cardiology
  • Cardiovascular physiology
patents chart

Application Date

Grant Date


Related Topics




Synodontis, Chip carriers, Bones of the foot, Semiconductor packages, Electronics manufacturing


Application Date


Grant Date



Related Topics

Synodontis, Chip carriers, Bones of the foot, Semiconductor packages, Electronics manufacturing



Latest XENIOS News

Xenios AG Receives Chinese Approval for ECMO Devices

Sep 30, 2021

Xenios AG Receives Chinese Approval for ECMO Devices Decision follows the approval of the Xenios console in December 2020. Image courtesy of PresseBox. PresseBox09.30.21   Xenios AG , a Fresenius Medical Care company, has received approval from the National Medical Products Administration (NMPA) in China for the Xenios console and patient kits for ECMO therapy. The approval for two patient kits in China follows NMPA’s approval of the Xenios console in December 2020. As a result, a complete Xenios system is now permitted for ECMO therapy in China. Xenios received the approval through a process called “Fast Registration.” This expedited process is only offered for products that, for example, are urgently needed for clinical use and can treat serious, life-threatening diseases. This Xenios ECMO complete system is certified in China for nine days application period. It is also the first ever “Fast Registration” for new imported medical devices in China. “We are particularly proud to have received this approval,” said Jörg Buschbell, CEO of Xenios AG. “In just over a year, we have gained access not only to the U.S. market, but also to the Chinese market for our ECMO therapy products. This marks another milestone for Xenios AG and Fresenius Medical Care.” “The expedited approval was a joint effort by Xenios and Fresenius Medical Care China Team. Since the beginning of the pandemic, they strived to make our advanced critical care products available in China for treating the critically ill patients,” said Harry De Wit, president and CEO of Fresenius Medical Care Asia Pacific. “The approval means that we will be able to support the Chinese critical care community further with our advanced developments, ultimately benefitting the patients.” ECMO stands for extracorporeal membrane oxygenation. In simple terms, the ECMO treatment bypasses the function of the lungs. The patient's blood is partially or completely freed from carbon dioxide outside the body and enriched with oxygen. The attending physician gains time to adjust the therapy according to the patient's needs, and the lungs are relieved, giving them time to heal. Xenios AG is a pioneer in extracorporeal heart and lung support. The Novalung and Medos products offer a wide range of heart and lung support products via a single platform, the Xenios console. Xenios' mission is to improve patient well-being and care. The Novalung therapy aims at a paradigm shift in lung support: enabling the treatment of patients who are more awake, more self-determined and more mobile. Xenios AG has been part of Fresenius Medical Care, the world's leading provider of products and services for people with kidney disease since the end of 2016. Xenios complements the group's portfolio in the area of holistic multi-organ support of Fresenius Medical Care. Medtronic plc 09.30.21 Business Wire 09.30.21 Business Wire 09.30.21 PR Newswire 09.30.21 GE Healthcare 09.30.21 Business Wire 09.30.21 Abbott Laboratories 09.30.21 Seegene Inc. 09.29.21 Business Wire 09.29.21 Globe Newswire 09.29.21 Globe Newswire 09.29.21 Siemens Healthineers 09.29.21 Future Market Insights 09.29.21 Amnovis 09.28.21 DeepLook Inc. 09.28.21

XENIOS Frequently Asked Questions (FAQ)

  • Where is XENIOS's headquarters?

    XENIOS's headquarters is located at Im Zukunftspark 1, Heilbronn.

  • What is XENIOS's latest funding round?

    XENIOS's latest funding round is Acquired.

  • Who are the investors of XENIOS?

    Investors of XENIOS include Fresenius Medical Care and Zukunftsfonds Heilbronn.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.